  |
Metadol®
Metadol® contains methadone hydrochloride and is approved in Canada as an analgesic in acute cancer pain, palliative care and chronic pain disorders and for detoxification or maintenance treatment of opioid-dependent individuals.
Twinject
Twinject is a pre-filled, pen size auto-injector with two doses of epinephrine for the emergency treatment of severe allergic reactions (anaphylaxis). The first dose is administered using the auto-injector. The second dose, if needed, is administered via a pre-filled syringe located inside the barrel of the device. Twinject is available in a compact, crush-resistant carrying case, with instructions for use attached to the device; it also has a small gauge needle. In addition, there will be a consumer campaign called Twinject Be Ready, which aims to provide comprehensive patient training and support. For more information about Twinject, please visit www.twinject.ca.
Testim®
Testim® 1% (testosterone gel) is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. It is a topical formulation that dries quickly when applied to the skin surface and that delivers physiologic amounts of testosterone, producing circulating testosterone levels that approximate normal levels seen in healthy men.
Each Testim® 1% 5 g tube contains testosterone 1% in a clear to translucent hydroalcoholic topical gel. Testim® 1% is supplied in unit-dose aluminum tubes with epoxy phenolic liners in cartons of 30.
www.testim.ca
Plan B®
(Levonorgestrel)
A New Generation Emergency Contraceptive
Pennsaid
Pennsaid®, a lotion approved by Health Canada for the treatment of symptoms of knee osteoarthritis.
Seasonale®
Seasonale® is an extended-cycle oral contraceptive. On September 30, 2005, Paladin filed on behalf of Duramed the New Drug Submission (NDS) for Seasonale® with the Therapeutic Products Directorate (TPD) of Health Canada. Currently, Seasonale® is only approved and marketed in the United States where it was launched in October 2003. For the fiscal year ended June 30, 2005, Barr recorded sales of Seasonale® of U.S. $87 million. Under the Seasonale® extended regimen, women take active tablets of 0.15 mg levonorgestrel/0.03 mg of ethinyl estradiol for 84 consecutive days, followed by seven days of placebo. The regimen is designed to reduce the number of withdrawal bleeding periods from 13 to four per year. By contrast, the majority of oral contraceptive products currently available are based on a regimen of 21 treatment days, followed by seven days of placebo.
Exclusive Canadian distributor for:
Duramed Pharmaceuticals, Inc.
New Jersey, U.S.
|
